Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D7AOL8
|
|||
| Drug Name |
BNT321
|
|||
| Synonyms |
MVT-5873
Click to Show/Hide
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Pancreatic cancer [ICD-11: 2C10; ICD-9: 157] | Phase 2 | [1] | |
| Company |
BioNTech
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Carbohydrate antigen 19-9 (CA 19-9) | Target Info | Inhibitor | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT03801915) Perioperative MVT-5873, a Fully Human Monoclonal Antibody Against a CA 19-9 Epitope, for Operable CA 19-9 Producing Pancreatic Cancers, Cholangiocarcinomas, and Metastatic Colorectal Cancers. U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of BioNTech. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.